CA-WASTEFUEL
10.3.2022 11:17:11 CET | Business Wire | Press release
WasteFuel and Maersk have today announced a commercial-scale bio-methanol partnership, which is set to help accelerate the decarbonisation of the shipping sector.
Maersk intends to buy 30,000 tons per year of WasteFuel bio-methanol, an order to help fulfil the demand of its 12 new green methanol powered ships planned to be operational by 2024.
Initially this green methanol will be made from the conversion of municipal waste in South America by 2024, but both partners expect expanding projects and production of green methanol further.
This announcement builds upon Maersk Growth’s investment in WasteFuel last year, under Its decarbonisation theme, as part of Maersk's strategy to reach net zero by 2040.
This partnership has significant implications for some of the largest consumer product businesses in the world, with green fuel set to reduce the emissions footprint of the products bought and shipped globally.
Speaking from Copenhagen, Denmark, Henriette Hallberg Thygesen, CEO of Fleet & Strategic Brands, A.P. Moller – Maersk said, “To drive the massive scale-up of green fuels we need to transition towards decarbonisation, production must increase in time. Green methanol is the only market-ready sustainable fuel available today for shipping and production must be accelerated through collaboration across the ecosystem and around the world. That is why these partnerships mark an important milestone to get the transition to green energy underway.”
Speaking from WasteFuel’s headquarters in Los Angeles, California, Trevor Neilson, Co-founder, Chairman and CEO said, "Last year, many of the world’s largest companies including Amazon, Ikea, Apple, Nestle and Patagonia pledged to reach net-zero emissions by 2050. Ships transport nearly as much as 90% of globally traded goods by volume and produce nearly 1.1 billion tons of carbon dioxide emissions, which rivals the annual output of Germany, the world’s sixth-largest emitter. Without green fuel solutions, corporate net-zero commitments will be impossible to meet."
Compared to conventional fuels, WasteFuel aims for its marine fuels to reduce CO2 emissions by 95%, to cut Nitrogen Oxide emissions by up to 80%, and to eliminate sulphur oxide and particulate matter emissions.
Maersk Growth, the Corporate Venture arm of A.P. Moller – Maersk announced their investment in WasteFuel in September 2021. With their investment, Morten Bo Christiansen, VP and Head of Decarbonisation at A.P. Moller – Maersk joined Trevor Neilson, Guillaume Lucci, Par Lindstrom, Bradley Ferrell, and Guy Oseary on WasteFuel’s Board of Directors.
WasteFuel, using proven technologies to convert waste - which would otherwise decompose releasing greenhouse gasses - into low carbon fuels, is driving solutions to decarbonise air, land, and sea transport. In addition to the green methanol project with Maersk, the company has several biorefinery projects underway including a project in the Philippines to produce Sustainable Aviation Fuel and bio-methanol in partnership with Prime Infra and NetJets and projects across the Americas and Asia to produce Renewable Natural Gas and green methanol.
About WasteFuel
WasteFuel uses proven technologies to address the climate emergency and revolutionise mobility. We convert municipal (trash) and agricultural waste into low-carbon fuels, renewable natural gas, and green methanol.
WasteFuel investors include Maersk, Marc Benioff’s TIME Ventures, i(x) Net Zero, NetJets, Prime Infra, Guy Oseary, and Aileen Getty.
For more information visit: www.wastefuel.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005116/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release
With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release
Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom